[LHN]
Subscribe
Open menu
MethodologySubmit a ClaimMedical Disclaimer

Does fisetin clear senescent cells in humans?

Fisetin is promoted as a senolytic supplement that clears senescent cells.

Simple answer

Fisetin has senolytic interest from preclinical research, but it is not proven to clear senescent cells in humans in a way that improves aging outcomes. The safer reading is: do not treat social media or clinic marketing as proof, and do not use this page for medical decisions.

Bottom line at a glance

Bottom line:Not provenEvidence:Mostly lab/animalRisk:Moderate riskStatus:Supplement status
What does evidence mean?
Interesting science, but not proof it works in people.
Why risk matters
There are meaningful uncertainty, interaction or overuse concerns.
Approval status
Sold as a supplement, which is not the same as drug approval.

Last checked: Jun 27, 2026

What people claim

The claim turns senolytic biology into a supplement outcome.

What we know

  • Preclinical senolytic signals are hypothesis-generating.
  • Human senescent-cell clearance and outcome evidence remain limited.
  • Supplement status does not prove efficacy.

What we do not know

  • It does not prove human senescent-cell clearance.
  • It does not prove healthspan benefit.
  • It does not prove all supplement products match research material.

What should you do with this information?

  • Use it to ask better questions.
  • Look for human evidence, not only exciting mechanisms or popularity.
  • Do not judge a claim by influencer attention or marketing language.

What not to do

  • Do not treat supplement availability as proof of benefit.
  • Do not build a self-directed senolytic routine from this page.
  • Ask a qualified clinician about interactions and conditions before acting.

Questions to ask a qualified clinician

  1. What exact medical indication is being discussed, and is it approved for that use?
  2. What human evidence exists for my situation, not just animals, cells or biomarkers?
  3. What monitoring, contraindications and interaction questions matter before any decision?
  4. What outcome would show benefit, and what outcome would show harm or no effect?

Want the deeper version?

Open these sections if you want the source detail, regulatory context and expert notes.

Show the evidenceSources, study type and where the claim gets weaker.+
Clinicaltrials

Shows registered studies and endpoints.

Publisher
ClinicalTrials.gov
Accessed
Jun 27, 2026
Study type
Regulatory Document

Limitations: Trial registration does not prove benefit; it shows a study has been registered.

Weakest link in the claim

  • The weak link is proving human senescent-cell clearance and clinical benefit.
Show regulatory detailApproval status is use-specific. Internet claims may not match reviewed uses.+
Status:Supplement statusWho might profit:Supplement brand
Show expert notesWhat would change our mind, money trail and related claims.+

What would change our mind

  • Human trials with senescence biomarkers and clinical outcomes.
  • Replication with standardized products.
  • Safety and interaction data in relevant populations.

Money trail

Who might profit:Supplement brand

Commercial context does not automatically make a claim false, but it changes how carefully the claim should be read.

  • Fisetin claims can be attached to supplement sales and longevity stack content.

FAQs

Does this page give a protocol?

No. LHN claim checks explain evidence, risk, regulatory status and source context. They do not provide personal medical instructions.

Is fisetin a proven senolytic in humans?

No. LHN classifies the human clearance claim as unproven.

Related claims

Related guides

Get the weekly longevity evidence briefing.

One plain-English email on the claims, studies and regulatory updates worth knowing - without protocols, hype or miracle claims.

No protocols. No miracle claims. No spam.

I'm new to longevityPeptides and regulationRapamycin and longevity drugsNAD and supplementsGene therapy frontierBiological age and testing